GSK is planning to cut some R&D jobs, impacting up to 350 positions worldwide. In the UK, fewer than 50 jobs will be affected, and in the US, the number is under 70. These figures might change slightly as the company finalizes its plans. Currently, GSK's global R&D team has around 12,000 people.
According to a GSK representative, these changes are meant to match the company's workforce with its main goals. They also want to put more money into tech, efficiency, and important R&D locations over the next five years. In 2024, GSK spent £6.4 billion ($8.7B) on R&D and intends to increase this investment, aiming to develop several major blockbuster drugs by 2031.
The U.S. will be a major focus for investment, with $30 billion set aside for R&D and supply chain improvements. These job cuts are happening as Luke Miels begins his time as CEO, but they're part of a wider reorganization that includes earlier layoffs in Massachusetts and changes to site locations.
Even with these reductions, GSK is still making key acquisitions, like the $2.2 billion purchase of Rapt Therapeutics, to strengthen its ability to the innovation.
Related News